">
Monday, 15 September 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 15 September 2025
News

Radio drug hits another hurdle

Posted 15 September 2025 AM

Germany headquartered Oncobeta Therapeutics has hit another hurdle in its attempt to secure public funding for its non-melanoma skin cancer treatment Rhenium-SCT.

An application seeking MBS listing for the epidermal radioisotope therapy, also known as Rhenium-188 (Re-188) brachytherapy and manufactured at the Australian Nuclear Science and Technology Organisation, was first knocked back by MSAC in July 2023. A resubmission considered at the April 2025 meeting has now been deferred.

To see the whole article, please login

Popular

Bride that made pharma history
Company rolls out 9000 job cuts
Pharma exits 27 markets
Radio drug hits another hurdle
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home